Bile acids (BAs) retention in the liver is a potent determinant of liver failure risk in chronic cholestatic diseases. Schematically, these diseases include « inherited » forms resulting from ABCB11, ATPB8, ABCB4, CFTR, JAGGED1 gene defects and acquired immune mediatedpathologies such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
Biliary drainage either internally or externally are well-known invasive procedures capable to reduce pruritus or retard the rate of progression to cirrhosis in these disorders (1, 2) . The rapid increase in our understanding of the molecular basis and pathophysiology of BA-related disorders provides now many opportunities for development of novel therapeutic approaches (3) . One of these is targeting one or several players of the gut-liver axis, namely ASBT, OST alpha/beta, FXR and FGF19 with the aim at reducing hepatic BA concentrations. The authors of the two studies suggest that ASBT inhibition could be a promising therapeutic approach for cholestatic liver diseases. Before accepting such a premise the expected bad consequences of interruption of the enterohepatic BA circulation in men need to be underlined.
Fat soluble vitamin deficiencies, hyperoxaluria and urolithiasis, increased incidence of pigment and cholesterol gallstone, diarrhea, colonic inflammation and carcinogenesis are potential consequences of long-term BAs malabsorption in men. Vitamins A and D are potent inducers of fgf15 and modulators of BA synthesis in mice (7) . Unfortunately, neither the status nor the possible role of these vitamins were explored in mice receiving ASBT inhibitors. Colonic inflammation were not detected in the Baghdasaryan's study, probably due to the absence of chenodeoxycholate in mice. However the risk of colorectal cancer associated with ASBT inhibition needs to be evaluated carefully. In a recent study, Asbt-deficient mice challenged with azoxymethane alone to induce aberrant crypt foci (the earliest histological marker of colon neoplasia), or a combination of AOM and dextran sulfate sodium to induce colon tumor formation exhibited a 54% increase in aberrant crypt foci and 70 and 59% increases in colon tumor number and size, respectively. compared to littermate controls. Asbt-deficient mice had a striking, 2-fold increase in the number of colon adenocarcinomas (8) .
Bile acid sequestrants are orally administered, non absobable cationic resins that have been used to treat hypercholesterolemia and bile acid malabsorption for many years. A more recently recognized therapeutic benefit of sequestrants is that they lower blood glucose concentrations in patients with insulin resistance. The sequestrant colesevelam is now approved for treating type 2 diabetes. Like ASBT inhibitors, sequestrants inhibit FXR activity, strongly suppress FGF15/19 expression and activate TGR5 in the colon and thus stimulate the expression and secretion of GLP-1 (9) . Because of these effects, it would be of great interest to determine whether sequestrants could alleviate liver injury in mdr2 -/-mice as ASBT inhibitors do.
Exploring the possible therapeutic benefit of drugs that decrease FXR and FGF15/19 seems nowadays paradoxical since the use of FXR agonists and the FGF19 derivative NGM282 is already in advanced progress in patients with fibrosing cholangiopathies (3). However, as for many other diseases, it can not be excluded that variable combination therapies targeting BA homeostasis will be the best way to offer a personalized and efficient therapeutic approach in the various inherited and acquired forms of chronic cholestatic diseases.
